ITCI - Intra-Cellular Therapies, Inc.
| Previous Close | 12.17 |
| Open | 12.20 |
| Bid | 12.22 x 800 |
| Ask | 12.24 x 900 |
| Day's Range | 11.67 - 12.52 |
| 52 Week Range | 10.21 - 23.64 |
| Volume | 482,460 |
| Avg. Volume | 321,691 |
| Market Cap | 673.016M |
| Beta (3Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.84 |
| Earnings Date | Aug 3, 2017 - Aug 7, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.67 |
- GlobeNewswire•4 days ago
Intra-Cellular Therapies Mourns the Passing of Co-Founder and Nobel Laureate, Dr. Paul Greengard
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, mourns the passing of our co-founder, Dr. Paul Greengard, a neuroscientist and Nobel Laureate whose pioneering research revolutionized our understanding of the biochemistry of the brain. Dr. Greengard’s Nobel prize-winning work in intracellular signaling was the foundation of the company’s formation in 2002. “We are deeply saddened by the news of Paul’s passing.
- GlobeNewswire•5 days ago
Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced additional results from its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone, an investigational drug, in patients with stable symptoms of schizophrenia. Results were also presented on the improvements in symptoms of depression in patients with moderate to severe co-morbid depression. The data were presented at the 2019 Congress of the Schizophrenia International Research Society (SIRS), which was held in Orlando, Florida, April 10-14, 2019. “Schizophrenia is a multidimensional illness with high rates of comorbidities, including depressive symptoms.
- Simply Wall St.•18 days ago
Investors Who Bought Intra-Cellular Therapies (NASDAQ:ITCI) Shares Three Years Ago Are Now Down 61%
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! If you love investing in stocks you're bound to buy some losers. Long term Intra-Cellular Therapies, Inc. (NASDAQ:ITCI...
- GlobeNewswire•25 days ago
Intra-Cellular Therapies Continues to Strengthen Its Commercial Leadership Team; John A. Bardi Appointed as Senior Vice President, Market Access, Policy and Government Affairs
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced the appointment of John A. Bardi as Senior Vice President for Market Access, Policy and Government Affairs. Mr. Bardi has over 30 years of biopharmaceutical and health system industry experience with a strong track record of innovation and building high-performing Market Access, Government Affairs, and Digital Medicine business development teams and capabilities across many disease areas.
- GlobeNewswire•2 months ago
Intra-Cellular Therapies to Present at The Cowen and Company 39th Annual Health Care Conference
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 39th Annual Healthcare Conference in Boston. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of ITCI earnings conference call or presentation 27-Feb-19 1:30pm GMT
Q4 2018 Intra-Cellular Therapies Inc Earnings Call
Motley Fool•2 months agoIntra-Cellular Therapies Inc (ITCI) Q4 2018 Earnings Conference Call Transcript
ITCI earnings call for the period ending December 31, 2018.
- GlobeNewswire•2 months ago
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Corporate Update
NEW YORK, Feb. 27, 2019 -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system.
- GlobeNewswire•2 months ago
Intra-Cellular Therapies to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference in New York. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.
- GlobeNewswire•2 months ago
Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Wednesday, February 27, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.
- GlobeNewswire•2 months ago
Detailed Research: Economic Perspectives on Tesla, Kura Oncology, ASML Holding N.V, Applied Industrial Technologies, Raven Industries, and Intra-Cellular Therapies — What Drives Growth in Today's Competitive Landscape
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Investor's Business Daily•2 months ago
Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst
An RBC Capital Markets analyst is "head over heels" for five biotech stocks, two with high Relative Strength Ratings. In afternoon action in the stock market, biotech stocks inched up.
- Simply Wall St.•3 months ago
Read This Before Buying Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
- ACCESSWIRE•4 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Intra-Cellular Therapies, Inc. - ITCI
NEW YORK, NY / ACCESSWIRE / January 3, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Intra-Cellular Therapies, Inc. ("Intra-Cellular" or the "Company") (NASDAQ: ITCI) Investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Intra-Cellular and certain of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. On December 18, 2018, Intra-Cellular Therapies issued a press release announcing that "an independent data monitoring committee (DMC) has completed a pre-specified interim analysis of the Company's ongoing clinical trial with low-dose lumateperone (9 mg ITI-007) for the treatment of agitation in patients with probable Alzheimer's disease (Study 201)." Intra-Cellular Therapies stated that "[t]he DMC concluded that Study 201 is not likely to meet its primary endpoint upon completion and therefore recommended the study should be stopped for futility.
- GlobeNewswire•4 months ago
Intra-Cellular Therapies to Present at the 37th Annual J.P. Morgan Healthcare Conference
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco at the Westin St. Francis Hotel. The live and archived webcast can be accessed under "Press Releases & Events" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease.
- Insider Monkey•4 months ago
Is Intra-Cellular Therapies Inc (ITCI) A Good Stock To Buy?
Many investors, including Paul Tudor Jones or Stan Druckenmiller, have been saying for a while now that the current market is overvalued due to a low interest rate environment that leads to companies swapping their equity for debt and focusing mostly on short-term performance such as beating the quarterly earnings estimates. In the fourth quarter, […]
- GlobeNewswire•4 months ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Intra-Cellular Therapies, Inc. (ITCI)
NEW YORK, Dec. 18, 2018 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intra-Cellular Therapies,.
- GlobeNewswire•4 months ago
Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer's Disease
“We are disappointed for patients suffering from Alzheimer's disease that the interim analysis did not detect a signal that would warrant continuation of this study. Effective clinical study design is a challenge, especially for a therapeutic indication for which there are no approved treatments," said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
- Simply Wall St.•4 months ago
How Should Investors React To Intra-Cellular Therapies, Inc.’s (NASDAQ:ITCI) CEO Pay?
Sharon Mates became the CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) in 2013. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at companies of similar Read More...
- GlobeNewswire•4 months ago
Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced favorable results from the second part of its open-label safety switching study (Study 303) assessing the effects of long-term administration of lumateperone in patients with stable symptoms of schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) held in Hollywood, FL, December 9-13, 2018. Poster T184 entitled "Long-Term Safety for Lumateperone (ITI-007) in the Treatment of Schizophrenia" is being presented today from 5:30 pm — 7:30 pm during Poster Session II. The poster presented data demonstrating that lumateperone, administered for up to one year, was generally well tolerated and exhibited statistically significant improvements from baseline on key safety measures of body weight, cardiometabolic and endocrine parameters, without motor side effects often associated with other antipsychotic medications.
- GlobeNewswire•4 months ago
Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia
Intra-Cellular Therapies, Inc. (ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for lumateperone, an investigational agent for the treatment of schizophrenia. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 27, 2019. “The FDA’s acceptance of our NDA submission for lumateperone for the treatment of schizophrenia represents an important milestone and brings us closer to offering a potential advance in the treatment of patients suffering from schizophrenia,” said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.
